Parkinson’s Disease Drugs Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented by Mechanism of Action (Dopamine Agonists, Anticholinergic, MAO-B Inhibitors, Amantadine, Carbidopa-levodopa, COMT Inhibitors, and Other Mechanisms of Action), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Others), By Region, & Competition, 2020-2030F

Market Overview

Global Parkinson’s Disease Drugs Market was valued at USD 5.55 Billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 7.45% through 2030. Parkinson's disease is a chronic and progressive neurodegenerative disorder of the central nervous system that primarily affects movement control. It is characterized by a range of motor symptoms and can also involve non-motor symptoms. Resting tremors are a hallmark symptom of Parkinson's disease. These involuntary shaking movements typically occur when the affected limb is at rest and often involve a rhythmic "pill-rolling" motion of the fingers. Muscle stiffness and increased resistance to passive movement are common in Parkinson's disease. This rigidity can affect various muscle groups and lead to a sense of physical discomfort. Balance problems and a tendency to fall can develop as Parkinson's disease progresses. Individuals may have difficulty maintaining an upright posture and may experience unexplained falls. Parkinson's disease can involve a range of non-motor symptoms, including mood changes (such as depression and anxiety), sleep disturbances, cognitive impairment, autonomic dysfunction (such as constipation and orthostatic hypotension), and sensory changes.

Parkinson's disease is becoming more common, with a growing number of diagnosed cases globally. This trend increases the need for effective pharmaceutical treatments. Pharmaceutical companies are investing in research and development to create more effective and innovative drugs for Parkinson's disease. This includes developing drugs that not only alleviate symptoms but also potentially slow the progression of the disease. Greater awareness of Parkinson's disease among healthcare professionals and the public has led to earlier diagnosis and treatment. This drives the demand for drugs to manage the condition. Beyond traditional treatments, there is growing interest in emerging therapies, such as gene therapies, stem cell therapies, and neuroprotective agents. These therapies offer the potential for disease modification, further driving the market.

Key Market Drivers

Advancements in Technology

Implantable or wearable devices that deliver medication continuously or on-demand have been developed. These devices can provide a more stable and consistent drug delivery, reducing motor fluctuations and the need for frequent dosing. Advances in drug formulation techniques have led to the development of extended-release and controlled-release formulations. These formulations can help maintain therapeutic drug levels in the body over an extended period, reducing the frequency of medication administration. Inhalable levodopa formulations have been developed to provide rapid relief of motor symptoms. These inhalers can be particularly beneficial for patients who experience sudden "off" periods. Research is ongoing to identify and develop neuroprotective drugs that may slow the progression of Parkinson's disease. These drugs aim to protect and preserve dopamine-producing neurons in the brain. Advances in genetic testing and biomarker identification are enabling more personalized treatment approaches. Tailoring medication regimens to an individual's genetic profile and disease stage can optimize treatment outcomes. Prodrugs are inactive compounds that convert into active drugs within the body. Some prodrugs have been designed to improve the delivery of levodopa, the primary treatment for PD, and reduce side effects.

Non-invasive focused ultrasound is being explored as a potential treatment for PD. This technology can be used to target and disrupt brain regions responsible for tremors and other motor symptoms. Deep Brain Stimulation (DBS) is a surgical procedure that involves implanting electrodes in the brain to modulate neural activity. Ongoing technological improvements in electrode design and stimulation techniques aim to enhance the effectiveness of DBS as a treatment option. The integration of telemedicine and remote monitoring technologies allows healthcare providers to monitor patients' symptoms and adjust medication regimens remotely, improving patient care and reducing the need for frequent in-person visits. Artificial intelligence and machine learning algorithms are being employed to analyze data from wearable devices and sensors to track disease progression and predict "off" periods, enabling more proactive medication adjustments. Virtual Reality (VR) -based rehabilitation programs are being developed to improve motor function and balance in PD patients. These technologies provide interactive and engaging exercises. This factor will help in the development of Global Parkinson’s Disease Drugs Market.

Rising Prevalence of Parkinson’s Disease

The increasing prevalence of Parkinson’s Disease (PD) is a major factor fueling the expansion of the global PD drugs market. The global prevalence of Parkinson’s Disease (PD) has doubled over the past 25 years, with 2019 estimates indicating that more than 8.5 million individuals were living with the condition. In the same year, PD accounted for approximately 5.8 million disability-adjusted life years (DALYs), reflecting an 81% surge since 2000. Additionally, the disease was responsible for 329,000 deaths in 2019, marking a more than 100% increase over two decades. These rising figures underscore the growing burden of PD on healthcare systems and reinforce the urgent demand for advanced treatment solutions and innovative therapies. As the number of diagnosed cases continues to rise worldwide, the demand for effective treatment options is growing significantly. This trend is driven by several interrelated factors, including demographic shifts, environmental triggers, and improved disease awareness. Below is an in-depth analysis of how this rising prevalence is shaping the market dynamics:

Parkinson’s Disease primarily affects individuals over the age of 60, with incidence rates increasing sharply in older populations. Parkinson’s Disease (PD) is the second most prevalent neurodegenerative disorder in the United States, with the majority of diagnoses occurring in individuals aged 60 and older. However, early-onset cases account for approximately 5% to 10% of total diagnoses, affecting patients under the age of 50. This growing incidence of PD across different age groups highlights the need for targeted treatment strategies and continued advancements in therapeutic development. According to global health studies, the proportion of elderly individuals is growing rapidly, particularly in developed economies such as the United States, Japan, and Europe. For instance, by 2050, the global population of individuals aged 60 and above is projected to reach 2.1 billion, doubling from current levels. Meanwhile, the number of people aged 80 and older is expected to triple the 2020 figures, reaching 426 million. This demographic shift is set to drive increased demand for age-related healthcare solutions, including treatments for neurodegenerative diseases such as Parkinson’s. Since age is the strongest risk factor for PD, the increasing elderly population directly correlates with a higher patient base, driving demand for pharmaceutical interventions.

Advancements in diagnostic techniques are leading to earlier and more accurate detection of Parkinson’s Disease. Innovations such as biomarker identification, AI-driven imaging, and genetic screening are helping physicians diagnose PD at earlier stages, increasing the number of identified patients who require treatment. As diagnostic capabilities improve, more individuals enter the treatment pipeline, boosting market demand for both existing and emerging drug therapies. Medical advancements have extended the lifespan of individuals with Parkinson’s Disease, resulting in longer treatment durations. Since PD is a progressive neurodegenerative disorder with no known cure, patients require lifelong medication. This extended treatment period significantly contributes to the growth of the PD drugs market, as patients depend on continuous drug therapies to manage symptoms, enhance quality of life, and slow disease progression. Greater public awareness, fueled by advocacy groups, research organizations, and patient communities, has led to more individuals seeking medical attention for Parkinson’s symptoms. High-profile initiatives by organizations such as the Michael J. Fox Foundation and the Parkinson’s Foundation have played a crucial role in promoting awareness, leading to earlier diagnoses and increasing the demand for drug therapies. Additionally, government-backed screening programs in countries with aging populations are further expanding the patient base.

Emerging Therapies

Emerging therapies in Parkinson's disease are innovative approaches that aim to provide more effective treatment options, potentially slow disease progression, and improve the overall quality of life for individuals living with this neurodegenerative condition. Gene therapy involves altering or replacing faulty genes to treat or prevent disease. In Parkinson's disease, researchers are exploring gene therapy approaches to enhance the production of dopamine or protect dopamine-producing neurons. Promising targets include the GDNF (glial cell-derived neurotrophic factor) gene. Stem cell therapies aim to replace damaged or lost dopamine-producing neurons in the brain. Researchers are investigating the use of various stem cell types, including induced pluripotent stem cells (iPSCs) and embryonic stem cells, to generate dopamine neurons for transplantation. Several drugs and compounds are under investigation for their potential to protect and preserve dopamine-producing neurons in the brain. These agents may have disease-modifying effects and slow the progression of Parkinson's disease. Alpha-synuclein is a protein that forms abnormal aggregates in the brains of individuals with Parkinson's disease. Therapies aimed at reducing alpha-synuclein aggregation or clearing existing aggregates are being explored as potential disease-modifying treatments. Inflammation in the brain is thought to play a role in the progression of Parkinson's disease. Immunotherapies and anti-inflammatory drugs are being investigated to determine if they can slow disease progression or reduce symptoms. Non-invasive focused ultrasound is being studied as a potential treatment for Parkinson's disease. It can be used to target and disrupt brain regions responsible for tremors and other motor symptoms.

Optogenetics is a cutting-edge technique that involves using light-sensitive proteins to control the activity of specific neurons in the brain. Researchers are exploring optogenetic approaches to modulate neural circuits involved in Parkinson's symptoms. Tau protein abnormalities have been associated with Parkinson's disease. Emerging therapies targeting tau protein aggregates are being investigated as potential disease-modifying treatments. Advances in biomarker research may lead to the development of therapies tailored to specific subtypes of Parkinson's disease. These therapies aim to target the underlying molecular mechanisms of the disease. Neurofeedback and Brain-Computer Interfaces (BCIs) are being explored to assist patients in regaining control over their movements and alleviate Parkinson's symptoms. These technologies provide real-time feedback and assist in motor rehabilitation. Tailoring treatment regimens to an individual's genetic profile and disease stage is a growing focus in Parkinson's disease management. Precision medicine approaches aim to optimize therapy for each patient's specific needs. Nanotechnology may offer novel drug delivery methods, such as nanoparticles that can target specific brain regions or deliver therapeutic agents more effectively to the brain. This factor will accelerate the demand of Global Parkinson’s Disease Drugs Market.

Download Free Sample Report

Key Market Challenges

Side Effects and Tolerability

Some Parkinson's disease drugs, particularly levodopa, can lead to motor fluctuations, including "on-off" periods, dyskinesias (involuntary movements), and wearing-off phenomena. These fluctuations can be disruptive and challenging to manage. Many Parkinson's drugs can cause gastrointestinal side effects such as nausea, vomiting, and constipation. These side effects can affect medication absorption and patient compliance. Dopaminergic medications, including dopamine agonists, can lead to psychiatric side effects like hallucinations, impulse control disorders, and mood disturbances. These can have a significant impact on a patient's mental well-being. Some medications may exacerbate cognitive impairment in Parkinson's disease patients, particularly in advanced stages of the disease. This can include impairments in memory, attention, and executive function. Parkinson's disease drugs can lower blood pressure, leading to orthostatic hypotension, a condition where blood pressure drops significantly upon standing. This can result in dizziness, falls, and fainting. Medications can affect sleep patterns, leading to insomnia or excessive daytime sleepiness. Sleep disturbances can further worsen the quality of life for patients. Dopamine agonists can sometimes cause impulsive behaviors, including gambling and hypersexuality. These behaviors can strain relationships and have financial and social consequences. Patients with Parkinson's disease often take multiple medications to manage their symptoms and comorbid conditions. Drug interactions can occur, potentially leading to adverse effects or reduced drug efficacy.

Limited Efficacy of Current Treatments

Over time, many patients with Parkinson's disease experience motor fluctuations, characterized by periods of "on" (when medication is working well) and "off" (when medication is less effective). These fluctuations can lead to unpredictable symptom changes and reduced quality of life. Levodopa, a common dopaminergic medication used in Parkinson's disease treatment, can lose its effectiveness over time. Patients may require higher doses, leading to increased risk of side effects. Parkinson's disease is associated with a range of non-motor symptoms, including cognitive impairment, depression, anxiety, sleep disturbances, and autonomic dysfunction. Current treatments often provide limited relief for these non-motor symptoms. While existing drugs can manage symptoms, they do not address the underlying neurodegenerative process that causes Parkinson's disease. As the disease progresses, patients may become less responsive to medication, and symptoms may worsen. Some patients develop tolerance to dopaminergic medications, leading to reduced effectiveness. Moreover, long-term use of these drugs can result in dyskinesias (involuntary movements) that are challenging to manage. Current treatments may not adequately address cognitive impairment, which can be a significant challenge for patients and caregivers.

Key Market Trends

Patient-Centric Approaches

Recognizing that Parkinson's disease can manifest differently in each patient, healthcare providers are increasingly tailoring treatment plans to the specific needs and characteristics of individuals. Genetic testing and other biomarker assessments may be used to determine the most appropriate medications and dosages. Patient-centric care emphasizes the importance of involving patients in their own care decisions. It considers their preferences, values, and goals when developing treatment plans. This approach fosters a collaborative relationship between patients and healthcare providers. Shared decision-making is a fundamental aspect of patient-centric care. It involves a two-way exchange of information and decision-making between patients and healthcare providers to determine the most suitable treatment options based on the patient's preferences and circumstances. Educating patients about their condition, treatment options, and self-management strategies is crucial. Empowering patients with knowledge enable them to actively participate in their care and make informed decisions. A patient-centric approach often involves a multidisciplinary care team, including neurologists, physical therapists, occupational therapists, speech therapists, and mental health professionals. This team collaborates to address the diverse needs of Parkinson's patients.

Segmental Insights

Mechanism of Action Insights

In 2024, MAO-B inhibitors segment emerges as the fastest growing in the Global Parkinson’s Disease Drugs in the forecast period and is predicted to continue expanding over the coming years. Dopamine and other chemicals in the brain are broken down by the Monoamine Oxidase Type B (MAO-B) enzyme in the human body. An MAO-B inhibitor, a medication, increases the amount of dopamine available for the brain to use, which can mildly alleviate several of Parkinson's Disease (PD) movement symptoms. To treat PD, MOA-B inhibitors have lately become popular. Over the projection period, this is anticipated to accelerate segment growth. Monoamine oxidase-B (MAO-B) inhibitors are commonly used to treat Parkinson's disease symptoms, according to the paper "Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease: Past, Present, and Future" published in February 2022.Parkinson's disease can be effectively treated in its early stages with MAO-B inhibitor monotherapy and in its later stages with MAO-B inhibitors used as adjuvant therapy. Growth in the segment is therefore anticipated because of research and development.

Download Free Sample Report

Regional Insights

The North America region emerges as the largest market in the Global Parkinson’s Disease Drugs Market in 2024. The United States currently controls a sizeable portion of the market in North America, and it is anticipated that it will continue to rule during the projection period. The high cost of healthcare, the dominance of large market players, the regular approval of new products, and the rise in Parkinson's disease patients can all be considered contributing causes.  Additionally, the FDA in the United States and other nations in the region has frequently approved products due to the rising number of cases of the condition in the nation. For instance, Parkinson's Disease (PD), the neurological condition with the greatest rate of growth in the United States and one of the conditions for which there is currently no cure, is treated with DHIVY, which was given FDA approval in November 2021. Over the course of the analysis period, the FDA's approvals are anticipated to support market expansion.

Recent Developments

• In February 2025, The U.S. FDA has granted approval for a next-generation Parkinson’s disease infusion device, set for market release in late 2025. Designed to deliver continuous, around-the-clock symptom relief, the therapy leverages advanced infusion technology to enhance disease management and improve patient outcomes. This milestone approval marks a significant advancement in treatment accessibility for Parkinson’s patients across the U.S.
• In November 2024, PRODUODOPA, a next-generation continuous infusion therapy for Parkinson’s disease, has successfully completed clinical trials in Europe. Designed for patients experiencing medication wear-off or dyskinesia, PRODUODOPA delivers a steady dose via a pump, mirroring the delivery mechanism of insulin pumps in diabetes care. Trial results indicate its potential to enhance symptom management while reducing patients' reliance on multiple daily oral doses.
• In October 2024, AbbVie secured U.S. FDA approval for VYALEV™ (foscarbidopa and foslevodopa), marking a breakthrough as the first and only 24-hour subcutaneous levodopa-based infusion therapy for advanced Parkinson’s disease. This approval positions AbbVie at the forefront of movement disorder treatments, addressing critical motor fluctuations in patients with progressive disease stages.
• In September 2024, A newly identified drug molecule shows promise in advancing treatments aimed at preventing Parkinson’s disease in younger patients, according to recent research. Scientists highlight its potential as a breakthrough, with the possibility of developing the first disease-modifying therapy for a specific subset of Parkinson’s patients, marking a significant step toward a curative approach.
• In September 2024, Amneal Pharmaceuticals, Inc. officially launched CREXONT® (carbidopa and levodopa) extended-release capsules, now widely available across U.S. pharmacies. CREXONT® is an innovative oral formulation designed for Parkinson’s disease treatment, integrating immediate-release granules with extended-release pellets to optimize therapeutic efficacy. This launch underscores Amneal’s commitment to advancing neurology care through differentiated, patient-centric solutionsn
• In May 2024, A Phase 3, randomized, double-blinded, double-dummy trial has yielded new data on ND0612, a continuous subcutaneous levodopa-carbidopa patch-pump therapy for Parkinson’s disease. Sponsored by the manufacturer, the study evaluated the treatment’s safety and efficacy in patients experiencing motor fluctuations. A total of 259 participants across 117 sites completed an open-label run-in phase (up to 12 weeks) to optimize individual regimens for both oral levodopa-carbidopa and ND0612 infusion, providing a robust foundation for assessing the therapy’s clinical benefits.
• In August 2023, Aspen Neuroscience announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application, granting the company clearance to advance ANPD001, its personalized autologous cell therapy for Parkinson’s Disease, into clinical trials. ANPD001 is designed to restore dopamine neurons lost to the disease, addressing a critical unmet need in Parkinson’s treatment.

Key Market Players

• Amneal Pharmaceuticals LLC
• AbbVie Inc.
• Boehringer Ingelheim International GmbH
• GSK plc
• Teva Pharmaceuticals Industries Ltd
• Pfizer Inc.
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Kissei Pharmaceutical Co., Ltd.
• AstraZeneca Plc
• Prevail Therapeutics (Eli Lilly and Company)
• Newron Pharmaceuticals SPA

Report Scope:

In this report, the Global Parkinson’s Disease Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

•  Parkinson’s Disease Drugs Market, By Mechanism of Action:

o   Dopamine Agonists

o   Anticholinergic

o   MAO-B Inhibitors

o   Amantadine

o   Carbidopa-levodopa

o   COMT Inhibitors

o   Other Mechanisms of Action

• Parkinson’s Disease Drugs Market, By Distribution Channel:

o   Retail Pharmacies

o   Hospital Pharmacies

o   Others

• Global Parkinson’s Disease Drugs Market, By region:

o   North America

§  United States

§  Canada

§  Mexico

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Australia

§  Japan

o   Europe

§  Germany

§  France

§  United Kingdom

§  Spain

§  Italy

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Parkinson’s Disease Drugs Market.

Available Customizations:

Global Parkinson’s Disease Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Parkinson’s Disease Drugs Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com